<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:07:45Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10289225" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10289225</identifier>
        <datestamp>2023-06-24</datestamp>
        <setSpec>lwwopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Otol Neurotol</journal-id>
              <journal-id journal-id-type="iso-abbrev">Otol Neurotol</journal-id>
              <journal-id journal-id-type="publisher-id">ON</journal-id>
              <journal-title-group>
                <journal-title>Otology &amp; Neurotology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1531-7129</issn>
              <issn pub-type="epub">1537-4505</issn>
              <publisher>
                <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10289225</article-id>
              <article-id pub-id-type="pmcid">PMC10289225</article-id>
              <article-id pub-id-type="pmc-uid">10289225</article-id>
              <article-id pub-id-type="pmid">37185596</article-id>
              <article-id pub-id-type="pmid">37185596</article-id>
              <article-id pub-id-type="publisher-id">ON_230367</article-id>
              <article-id pub-id-type="doi">10.1097/MAO.0000000000003886</article-id>
              <article-id pub-id-type="art-access-id">00016</article-id>
              <article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Vestibular Disorders</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Efficacy of Intratympanic OTO-104 for the Treatment of Ménière's Disease: The Outcome of Three Randomized, Double-Blind, Placebo-Controlled Studies</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Phillips</surname>
                    <given-names>John</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">∗</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mikulec</surname>
                    <given-names>Anthony A.</given-names>
                  </name>
                  <email>tonymikulec@gmail.com</email>
                  <xref rid="aff2" ref-type="aff">†</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Robinson</surname>
                    <given-names>James M.</given-names>
                  </name>
                  <email>james.mac.robinson@gmail.com</email>
                  <xref rid="aff3" ref-type="aff">‡</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Skarinsky</surname>
                    <given-names>David</given-names>
                  </name>
                  <email>david.skarinsky@gmail.com</email>
                  <xref rid="aff3" ref-type="aff">‡</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Anderson</surname>
                    <given-names>Jeffery J.</given-names>
                  </name>
                  <email>jeffanderson@san.rr.com</email>
                  <xref rid="aff3" ref-type="aff">‡</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>∗</label>Department of Otolaryngology, Norfolk &amp; Norwich University Hospitals NHS Foundation Trust, Norwich, UK</aff>
              <aff id="aff2"><label>†</label>Department of Otolaryngology, Saint Louis University School of Medicine, St. Louis, Missouri</aff>
              <aff id="aff3"><label>‡</label>Otonomy, Inc., San Diego, CA</aff>
              <author-notes>
                <corresp id="corr1">Address correspondence and reprint requests to John Phillips, Ph.D., F.R.C.S. (ORL-HNS), Department of Otolaryngology, Norfolk &amp; Norwich University Hospitals NHS Foundation Trust, Colney Lane, Norwich NR4 7UY, UK; E-mail: <email>john.phillips@mac.com</email></corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <month>7</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>22</day>
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <volume>44</volume>
              <issue>6</issue>
              <fpage>584</fpage>
              <lpage>592</lpage>
              <permissions>
                <copyright-statement>Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of Otology &amp; Neurotology, Inc.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <copyright-holder>Wolters Kluwer Health, Inc. All rights reserved.</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="on-44-0584.pdf"/>
              <abstract>
                <title>Objective</title>
                <p>To determine the efficacy of intratympanic OTO-104 for the treatment of Ménière's disease.</p>
                <sec>
                  <title>Study Designs</title>
                  <p>Three randomized, double-blind, placebo-controlled, multicenter studies of OTO-104 in patients with Ménière's disease.</p>
                </sec>
                <sec>
                  <title>Setting</title>
                  <p>The United States and throughout Europe.</p>
                </sec>
                <sec>
                  <title>Patients</title>
                  <p>Individuals with Ménière's disease aged 18 to 85 years.</p>
                </sec>
                <sec>
                  <title>Interventions</title>
                  <p>All three studies were conducted according to a similar protocol, whereby after a 1-month lead-in period, eligible patients received a single intratympanic injection of either 12 mg OTO-104 (otic formulation of dexamethasone in thermosensitive poloxamer) or placebo (1:1) and were observed for 3 months.</p>
                </sec>
                <sec>
                  <title>Main Outcome Measures</title>
                  <p>The primary efficacy endpoint was measured by the number of definitive vertigo days (DVDs) at month 3. Secondary objective was OTO-104 safety and tolerability including adverse events, audiometry, tympanometry, and otoscopic examinations.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Although OTO-104 demonstrated numerically greater reductions in DVD compared with placebo across all three studies, statistical significance versus placebo (primary efficacy endpoint) was only achieved in one study, the AVERTS-2 study (n = 174, <italic toggle="yes">p</italic> = 0.029). Secondary vertigo efficacy endpoints were statistically significant at month 3 in that study including vertigo severity, the effect of vertigo on daily activity (days at home sick or bedridden), and vertigo frequency. In the AVERTS-1 study, which did not meet the primary endpoint, a subgroup analysis of the 115 patients (69.7% of study population) who did not previously receive intratympanic steroid injections demonstrated that OTO-104 patients had significantly lower mean DVD at month 3 than patients receiving placebo (1.9 for OTO-104 versus 3.0 for placebo; <italic toggle="yes">p</italic> = 0.045). Importantly, a significant placebo response was observed across studies in Ménière's disease patients. OTO-104 and the intratympanic injection procedure were well tolerated.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>In all three high-quality, randomized, double-blind, placebo-controlled, multicenter studies, a single intratympanic injection of 12 mg OTO-104 demonstrated numerically greater reductions in vertigo versus placebo in patients with Ménière's disease, but statistical separation from placebo was demonstrated in only one of the studies. OTO-104 was safe and well tolerated.</p>
                  <p>(Otonomy, Inc. funded; NCT02717442, NCT02612337, NCT03664674).</p>
                </sec>
              </abstract>
              <kwd-group>
                <title>Key Words</title>
                <kwd>Ménière's disease</kwd>
                <kwd>Steroids</kwd>
                <kwd>Vertigo</kwd>
              </kwd-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>SDC</meta-name>
                  <meta-value>T</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>OPEN-ACCESS</meta-name>
                  <meta-value>TRUE</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro">
              <title>INTRODUCTION</title>
              <p>Ménière's disease is a chronic idiopathic condition of the inner ear predominantly characterized by spontaneous episodes of vertigo; other symptoms include fluctuating hearing loss, tinnitus, and aural fullness (<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref>). The lifetime prevalence of Ménière's disease in the United States has been reported to be 190 per 100,000 people (<xref rid="bib3" ref-type="bibr">3</xref>), with an annual incidence of 15.3 per 100,000 people (<xref rid="bib4" ref-type="bibr">4</xref>). In addition to the physical symptoms of Ménière's disease, affected individuals endure a material impairment of their quality of life (<xref rid="bib5" ref-type="bibr">5</xref>,<xref rid="bib6" ref-type="bibr">6</xref>). The economic impact of this condition can be overwhelming for patients and their families; a broader societal impact of Ménière's disease has recently been established (<xref rid="bib7" ref-type="bibr">7</xref>).</p>
              <p>The underlying etiology of Ménière's disease is unknown, and there is no current cure. Evidence-based treatment options are limited and are directed at either relieving acute symptoms or ablating the function of the inner ear via the use of ototoxic medications and/or by surgical destruction. Repeated intratympanic injections of aqueous corticosteroid formulations have been associated with clinical improvement in patients with Ménière's disease (<xref rid="bib8" ref-type="bibr">8</xref>–<xref rid="bib10" ref-type="bibr">10</xref>). A number of mechanisms to support the physiological role of corticosteroids in Ménière's disease have been proposed (<xref rid="bib11" ref-type="bibr">11</xref>). For example, corticosteroids are known to modify the regulation of inner ear epithelial ion transport by activating the outflow of sodium via epithelial sodium channels and sodium/potassium ATPases (<xref rid="bib12" ref-type="bibr">12</xref>). Sodium movement from the labyrinth fluid to the epithelial compartment is hypothesized to result in a reduction in endolymph fluid volume and could translate to a reduction in Ménière's symptoms, such as vertigo. The administration of corticosteroids directly into the middle ear allows maximal drug exposure at the interface with the inner ear while minimizing the potential for systemic adverse effects.</p>
              <p>OTO-104 is a suspension of dexamethasone in a buffered solution of the thermoreversible glycol polymer, poloxamer 407. It has been formulated for intratympanic application over the round window niche where it gels within seconds at body temperature and provides sustained exposure of dexamethasone to the inner ear for 2 to 3 months in animals (<xref rid="bib13" ref-type="bibr">13</xref>). Preliminary clinical studies have consistently demonstrated a beneficial effect of OTO-104 when compared with placebo with a good safety profile (<xref rid="bib14" ref-type="bibr">14</xref>,<xref rid="bib15" ref-type="bibr">15</xref>). Repeated intratympanic injections of aqueous corticosteroid have been associated with clinical improvement in patients with Ménière's disease that are comparable with similar, but destructive, treatments of this condition (<xref rid="bib16" ref-type="bibr">16</xref>). This article presents the results of three randomized, double-blind, placebo-controlled, multicenter phase 3 studies that have taken place in the United States and Europe, to determine whether OTO-104 provides prophylaxis for the dominant symptom of Ménière's disease: recurrent vertigo.</p>
            </sec>
            <sec sec-type="methods">
              <title>MATERIALS AND METHODS</title>
              <sec sec-type="subjects">
                <title>Study Design and Patients</title>
                <p>Three randomized, double-blind, placebo-controlled, multicenter phase 3 studies were conducted in the United States and Europe. For the purpose of this article, the first study refers to the US study (AVERTS-1; first subject enrolled October 25, 2015; last subject completed July 18, 2017), the second study refers to the European study (AVERTS-2; first subject enrolled March 21, 2016; last subject completed September 15, 2017), and the third study refers to the final international study that was conducted in the United States and Europe (811; first subject enrolled August 27, 2018; last subject completed December 22, 2020). All three studies were registered on ClinicalTrials.gov (AVERTS-1 [NCT02612337], AVERTS-2 [NCT02717442], and 811 [NCT03664674]). All studies were conducted in compliance with the applicable regulatory requirements, Declaration of Helsinki (<xref rid="bib17" ref-type="bibr">17</xref>), Good Clinical Practice (<xref rid="bib18" ref-type="bibr">18</xref>), and central and local Ethics Committee approvals. All patients were provided written informed consent before initiation of study participation.</p>
                <p>The study designs and protocols for AVERTS-1 and AVERTS-2 were identical. The 811 protocol was similar in design to the pervious protocols but included refined eligibility criteria after reviewing the results from the first two studies to ensure the Ménière's disease diagnosis was met and to limit placebo response. Refinement to the eligibility criteria 1) better excluded patients with vestibular migraine, 2) ensured hearing loss criteria were adequately met, and 3) excluded any pervious use of intratympanic steroids. For all three studies, men or women (18–85 yr) were enrolled who met the following criteria: definitive diagnosis of unilateral Ménière's disease by 1995 American Academy of Otolaryngology–Head and Neck Surgery criteria; reports active, definitive vertigo episodes for previous 2 months; documented asymmetric sensorineural hearing loss at screening or within past 12 months (<xref rid="bib1" ref-type="bibr">1</xref>) (arithmetic mean of hearing thresholds, pure-tone average [PTA], at 250, 500 and 1000 Hz of 15 dB or higher than the PTA of 1000, 2000, and 3000 Hz; arithmetic mean of PTA at 500, 1000, 2000, and 3,000 Hz that was 20 dB or poorer in the ear in question than on opposite side or audiogram characteristic of Ménière's disease based on judgment of investigator); no history of intratympanic gentamicin or endolymphatic sac surgery; no systemic or intratympanic steroids within 1 month before entering the lead-in period for AVERTS-1 and AVERTS-2 and no systemic steroids within 1 month of entering the lead-in period; and no history of intratympanic steroids for 811 study. Patients were allowed to continue stable doses of betahistine. In addition, during the 28-day lead-in period, patients reported their daily vertigo experience using a telephone diary (Supplemental Appendix A, <ext-link xlink:href="http://links.lww.com/MAO/B619" ext-link-type="uri">http://links.lww.com/MAO/B619</ext-link>). Patients were required to report between 4 and 22 definitive vertigo days (DVDs; a vertigo attack lasting at least 20 min corresponding to a Vertigo Severity Score ≥2) and complete at least 22 of 28 daily entries for study entry.</p>
              </sec>
              <sec>
                <title>Randomization and Masking</title>
                <p>Eligible patients were randomized to receive OTO-104 or placebo using a 1:1 allocation ratio and stratified by sex. Further details regarding this process are provided as Supplemental Appendix B, <ext-link xlink:href="http://links.lww.com/MAO/B620" ext-link-type="uri">http://links.lww.com/MAO/B620</ext-link>.</p>
              </sec>
              <sec sec-type="methods">
                <title>Procedures</title>
                <p>OTO-104 (12 mg) or placebo (OTO-104 vehicle) was administered as a single 0.2-mL intratympanic injection to the affected ear. The tympanic membrane was anesthetized with EMLA cream or similar lidocaine/prilocaine preparation (use of phenol was prohibited). OTO-104 or placebo was injected slowly, taking care not to insert the needle further than necessary.</p>
              </sec>
              <sec>
                <title>Outcomes</title>
                <p>Patients recorded their daily vertigo experience throughout the 28-day lead-in period and for 3 months after dosing. Patients visited the study site at months 1, 2, and 3 (end of study) for additional efficacy and safety assessments.</p>
                <p>The daily vertigo diary developed by Gates (<xref rid="bib19" ref-type="bibr">19</xref>) was adapted to an Interactive Voice Response System (or phone diary; Supplemental Appendix A, <ext-link xlink:href="http://links.lww.com/MAO/B619" ext-link-type="uri">http://links.lww.com/MAO/B619</ext-link>). Occurrence of a definitive vertigo episode for a given day was defined as a Vertigo Severity Score ≥2. If multiple attacks occurred on the same day, the severity of the worst attack was scored. Vertigo diary reports were delivered each day via telephone and could not be revised retrospectively, thereby ruling out recall bias. Patients were able to record missed diary entries for a maximum of 1 day after a missed entry. The SF-36, a validated, 36-item, multipurpose, short-form health survey was also administered on day 1, and months 1, 2, and 3 (<xref rid="bib20" ref-type="bibr">20</xref>,<xref rid="bib21" ref-type="bibr">21</xref>) for the AVERTS-1 and AVERTS-2 studies. Only the Social Functioning Subscale of the SF-36 was administered in the 811 study (day 1, month 2, and month 3). For the 811 study, the Patient Global Impression of Change (PGIC) was used to assess overall Menière's disease status since the beginning of the study; this patient-reported outcome was administered at month 2 and month 3.</p>
                <p>Further details regarding safety evaluation and statistical considerations are provided as Supplemental Appendix C, <ext-link xlink:href="http://links.lww.com/MAO/B621" ext-link-type="uri">http://links.lww.com/MAO/B621</ext-link>, and Appendix D, <ext-link xlink:href="http://links.lww.com/MAO/B622" ext-link-type="uri">http://links.lww.com/MAO/B622</ext-link> respectively.</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>RESULTS</title>
              <p>A total of 165, 174, and 148 patients, respectively, were randomized and received either OTO-104 or placebo in the three studies (AVERTS-1, AVERTS-2, and 811, respectively; Fig. <xref rid="F1" ref-type="fig">1</xref>, A–C). Most patients who failed to qualify did not meet the lead-in period requirement of at least 4 but no more than 22 DVDs over the 28-day period; most ineligible patients had fewer than 4 DVDs. The studies were conducted in 64 centers in the United States, 57 centers in Europe, and 66 centers in Europe/the United Kingdom/the United States, for the AVERTS-1, AVERTS-2, and 811 studies, respectively. The AVERTS-2 study was terminated early (sponsor's decision) after all patients were randomized and 111 patients completed the final study visit (month 3), whereas AVERTS-1 and 811 studies were completed as planned.</p>
              <fig position="float" id="F1">
                <label>FIG. 1</label>
                <caption>
                  <p><italic toggle="yes">A</italic>, AVERTS-1 enrollment, randomization, and treatment. <italic toggle="yes">B</italic>, AVERTS-2 enrollment, randomization, and treatment. <italic toggle="yes">C</italic>, 811 study enrollment, randomization, and treatment.</p>
                </caption>
                <graphic xlink:href="on-44-0584-g001" position="float"/>
              </fig>
              <p>Demographics were balanced across OTO-104 and placebo groups in all three studies (Table <xref rid="T1" ref-type="table">1</xref>). Baseline Ménière's disease characteristics were also generally balanced across treatment groups in each study (Table <xref rid="T2" ref-type="table">2</xref>). For most patients, the mean duration of Ménière's disease was 5 years or less, which likely coincides with the early stages of the disease in which patients are seeking treatment and likely to enroll in a study. For AVERTS-1, 30.3% of patients had received previous intratympanic steroid injections, compared with 6.9% of patients in the AVERTS-2 study. Intratympanic steroids were excluded from the 811 study. The mean DVD count during the 28-day lead-in period was also similar between studies and treatment groups ranging from 8.4 to 9.2 DVD for treatment groups. In addition, the most recorded category of hearing loss from PTA was 56 to 70 dB for each study (35.8% for AVERTS-1, 32.8% for AVERTS-2, and 34.5% for 811 studies) with all category incidences similar for OTO-104 and placebo groups.</p>
              <table-wrap position="float" id="T1">
                <label>TABLE 1</label>
                <caption>
                  <p>
Patient demographics and study regions
</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr valign="top">
                      <th rowspan="2" colspan="1"/>
                      <th align="center" colspan="3" rowspan="1">AVERTS-1</th>
                      <th align="center" colspan="3" rowspan="1">AVERTS-2</th>
                      <th align="center" colspan="3" rowspan="1">811</th>
                    </tr>
                    <tr valign="top">
                      <th align="center" rowspan="1" colspan="1">OTO-104 (n = 83)</th>
                      <th align="center" rowspan="1" colspan="1">Placebo (n = 82)</th>
                      <th align="center" rowspan="1" colspan="1">Total (N = 165)</th>
                      <th align="center" rowspan="1" colspan="1">OTO-104 (n = 86)</th>
                      <th align="center" rowspan="1" colspan="1">Placebo (n = 88)</th>
                      <th align="center" rowspan="1" colspan="1">Total (N = 174)</th>
                      <th align="center" rowspan="1" colspan="1">OTO-104 (n = 73)</th>
                      <th align="center" rowspan="1" colspan="1">Placebo (n = 75)</th>
                      <th align="center" rowspan="1" colspan="1">Total (N = 148)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1">Sex, n (%)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Male</td>
                      <td align="char" char="(" rowspan="1" colspan="1">35 (42.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">36 (43.9)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">71 (43.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">42 (48.8)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">40 (45.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">82 (47.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">29 (39.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">31 (41.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">60 (40.5)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Female</td>
                      <td align="char" char="(" rowspan="1" colspan="1">48 (57.8)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">46 (56.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">94 (57.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">44 (51.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">48 (54.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">92 (52.9)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">44 (60.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">44 (58.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">88 (59.5)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1">Age, yr</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Mean (SD)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">54.7 (13.12)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">56.7 (12.27)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">55.7 (12.71)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">51.8 (12.13)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">52.6 (13.24)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">52.2 (12.67)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">55.7 (12.58)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">54.9 (12.40)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">55.3 (12.45)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1">Race, n (%)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> White</td>
                      <td align="char" char="(" rowspan="1" colspan="1">74 (89.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">80 (97.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">154 (93.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">82 (95.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">82 (93.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">164 (94.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">73 (100)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">71 (94.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">144 (97.3)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Black or African American</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8 (9.6)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8 (4.8)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Asian</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">2 (1.1)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (0.7)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> American Indian/Alaskan Native</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (0.6)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Not applicable</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.2)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (0.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (3.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">5 (5.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8 (4.6)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Other</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (0.6)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (4.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (2.0)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1">Ethnicity, n (%)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Hispanic or Latino</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8 (9.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">7 (8.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">15 (9.1)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (0.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">2 (2.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (2.0)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Not Hispanic or Latino</td>
                      <td align="char" char="(" rowspan="1" colspan="1">73 (88.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">75 (91.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">148 (89.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">77 (89.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">75 (85.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">152 (87.4)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">71 (97.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">73 (97.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">144 (97.3)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Not reported</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.2)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (0.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">7 (8.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">7 (8.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">14 (8.0)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (0.7)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Unknown</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.2)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (0.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">2 (2.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">5 (5.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">7 (4.0)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1">Region, n (%)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> North America</td>
                      <td align="char" char="(" rowspan="1" colspan="1">83 (100.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">82 (100.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">165 (100.0)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8 (11.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">13 (17.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">21 (14.2)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> United States</td>
                      <td align="char" char="(" rowspan="1" colspan="1">83 (100.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">82 (100.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">165 (100.0)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8 (11.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">13 (17.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">21 (14.2)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Europe</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">86 (100.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">88 (100.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">174 (100.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">65 (89.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">62 (82.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">127 (85.8)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Belgium</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (3.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">5 (5.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8 (4.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (4.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">6 (8.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">9 (6.1)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> France</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (4.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">5 (5.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">9 (5.2)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Germany</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">13 (15.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">15 (17.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">28 (16.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">11 (15.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (5.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">15 (10.1)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Italy</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">12 (14.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">6 (6.8)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">18 (10.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">7 (9.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">5 (6.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">12 (8.1)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Poland</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">28 (32.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">34 (38.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">62 (35.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">31 (42.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">29 (38.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">60 (40.5)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Spain</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (4.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (2.7)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Turkey</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (4.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8 (10.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">11 (7.4)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> United Kingdom</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">26 (30.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">23 (26.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">49 (28.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">7 (9.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">9 (12.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">16 (10.8)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn fn-type="other">
                    <p>SD indicates standard deviation.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <table-wrap position="float" id="T2">
                <label>TABLE 2</label>
                <caption>
                  <p>
Baseline disease characteristics
</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <thead>
                    <tr valign="top">
                      <th rowspan="2" colspan="1"/>
                      <th align="center" colspan="3" rowspan="1">AVERTS-1</th>
                      <th align="center" colspan="3" rowspan="1">AVERTS-2</th>
                      <th align="center" colspan="3" rowspan="1">811</th>
                    </tr>
                    <tr valign="top">
                      <th align="center" rowspan="1" colspan="1">OTO-104 (n = 83)</th>
                      <th align="center" rowspan="1" colspan="1">Placebo (n = 82)</th>
                      <th align="center" rowspan="1" colspan="1">Total (N = 165)</th>
                      <th align="center" rowspan="1" colspan="1">OTO-104 (n = 86)</th>
                      <th align="center" rowspan="1" colspan="1">Placebo (n = 88)</th>
                      <th align="center" rowspan="1" colspan="1">Total (N = 174)</th>
                      <th align="center" rowspan="1" colspan="1">OTO-104 (n = 73)</th>
                      <th align="center" rowspan="1" colspan="1">Placebo (n = 75)</th>
                      <th align="center" rowspan="1" colspan="1">Total (N = 148)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1">Ménière's duration (yr), n (%)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> ≤5</td>
                      <td align="char" char="(" rowspan="1" colspan="1">67 (80.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">57 (69.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">124 (75.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">64 (74.4)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">70 (79.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">134 (77.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">61 (83.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">53 (70.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">114 (77.0)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> 6–10</td>
                      <td align="char" char="(" rowspan="1" colspan="1">9 (10.8)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">10 (12.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">19 (11.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">12 (14.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8 (9.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">20 (11.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">9 (12.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">13 (17.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">22 (14.9)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> 11–15</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (3.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8 (9.8)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">11 (6.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">5 (5.8)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (4.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">9 (5.2)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (5.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (2.7)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> &gt;15</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (4.8)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">7 (8.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">11 (6.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">5 (5.8)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">6 (6.8)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">11 (6.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (4.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">5 (6.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8 (5.4)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" colspan="4" rowspan="1">Previous IT steroid injection, n (%)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Yes</td>
                      <td align="char" char="(" rowspan="1" colspan="1">20 (24.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">30 (36.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">50 (30.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">5 (5.8)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">7 (8.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">12 (6.9)</td>
                      <td align="center" rowspan="1" colspan="1">—<italic toggle="yes"><sup>a</sup></italic></td>
                      <td align="center" rowspan="1" colspan="1">—</td>
                      <td align="center" rowspan="1" colspan="1">—</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> No</td>
                      <td align="char" char="(" rowspan="1" colspan="1">63 (75.9)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">52 (63.4)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">115 (69.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">80 (93.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">80 (90.9)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">160 (92.0)</td>
                      <td align="center" rowspan="1" colspan="1">—</td>
                      <td align="center" rowspan="1" colspan="1">—</td>
                      <td align="center" rowspan="1" colspan="1">—</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> Unknown</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">2 (1.1)</td>
                      <td align="center" rowspan="1" colspan="1">—</td>
                      <td align="center" rowspan="1" colspan="1">—</td>
                      <td align="center" rowspan="1" colspan="1">—</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1">Lead-in DVD count, mean (SD)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8.4 (4.01)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8.9 (4.24)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8.7 (4.12)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">9.0 (4.60)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">9.2 (4.64)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">9.1 (4.61)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8.8 (4.72)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">9.2 (4.40)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">9.0 (4.55)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1">Lead-in mean Vertigo Severity Score, mean (SD)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">0.88 (0.397)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">0.94 (0.410)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">0.91 (0.403)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">0.97 (0.452)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">0.99 (0.454)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">0.98 (0.452)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">0.92 (0.455)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1.01 (0.394)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">0.97 (0.426)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" colspan="4" rowspan="1">Degree of hearing loss from PTA (dB) category, n (%)</td>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> ≤15</td>
                      <td align="char" char="(" rowspan="1" colspan="1">6 (7.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (4.9)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">10 (6.1)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (4.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (2.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">2 (2.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (2.0)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> 16–26</td>
                      <td align="char" char="(" rowspan="1" colspan="1">6 (7.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (4.9)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">10 (6.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">7 (8.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">6 (6.8)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">13 (7.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (5.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">5 (6.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">9 (6.1)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> 26–40</td>
                      <td align="char" char="(" rowspan="1" colspan="1">13 (15.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">15 (18.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">28 (17.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">15 (17.4)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">15 (17.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">30 (17.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">19 (26.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">12 (16.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">31 (20.9)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> 41–55</td>
                      <td align="char" char="(" rowspan="1" colspan="1">21 (25.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">18 (22.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">39 (23.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">17 (19.8)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">22 (25.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">39 (22.4)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">16 (21.9)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">18 (24.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">34 (23.0)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> 56–70</td>
                      <td align="char" char="(" rowspan="1" colspan="1">28 (33.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">31 (37.8)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">59 (35.8)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">32 (37.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">25 (28.4)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">57 (32.8)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">20 (27.4)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">31 (41.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">51 (34.5)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> 71–90</td>
                      <td align="char" char="(" rowspan="1" colspan="1">6 (7.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">9 (11.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">15 (9.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">12 (14.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">15 (17.0)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">27 (15.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">10 (13.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">8 (10.7)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">18 (12.2)</td>
                    </tr>
                    <tr valign="top">
                      <td align="left" rowspan="1" colspan="1"> &gt;90</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (3.6)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.2)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (2.4)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">3 (3.5)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.1)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">4 (2.3)</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (1.4)</td>
                      <td align="center" rowspan="1" colspan="1">0</td>
                      <td align="char" char="(" rowspan="1" colspan="1">1 (0.7)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn fn-type="other">
                    <p>DVD indicates definitive vertigo days; IT, intratympanic; PTA, pure-tone average; SD, standard deviation.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <sec>
                <title>Efficacy</title>
                <sec>
                  <title>AVERTS-1</title>
                  <p>In the AVERTS-1 study, although the OTO-104 treatment group had lower adjusted mean DVD than placebo at month 3, the difference was not statistically significant (2.2 for OTO-104 versus 2.4 for placebo; <italic toggle="yes">p</italic> = 0.623; Fig. <xref rid="F2" ref-type="fig">2</xref>A). Secondary endpoints of mean vertigo severity score at month 3 (0.408 for OTO-104 versus 0.403 for placebo; <italic toggle="yes">p</italic> = 0.932), change from baseline in vertigo frequency at month 3 (−0.173 for OTO-104 versus −0.173 for placebo; <italic toggle="yes">p</italic> = 0.993), and effect of vertigo on days sick at home or bedridden at month 3 (0.590 for OTO-104 versus 0.579 for placebo; <italic toggle="yes">p</italic> = 0.943) were not different between OTO-104 and placebo groups (Table <xref rid="T3" ref-type="table">3</xref>). Also, the SF-36 physical and mental health summaries at month 3 were not significantly different between OTO-104 and placebo groups (data not shown).</p>
                  <fig position="float" id="F2">
                    <label>FIG. 2</label>
                    <caption>
                      <p>Effect of OTO-104 on mean monthly definitive vertigo days.</p>
                    </caption>
                    <graphic xlink:href="on-44-0584-g002" position="float"/>
                  </fig>
                  <table-wrap position="float" id="T3">
                    <label>TABLE 3</label>
                    <caption>
                      <p>
Key secondary endpoints at month 3 by study and treatment groups
</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <thead>
                        <tr valign="top">
                          <th align="left" rowspan="2" colspan="1">Variable</th>
                          <th align="center" colspan="2" rowspan="1">AVERTS-1</th>
                          <th align="center" colspan="2" rowspan="1">AVERTS-2</th>
                          <th align="center" colspan="2" rowspan="1">811</th>
                        </tr>
                        <tr valign="top">
                          <th align="center" rowspan="1" colspan="1">OTO-104 (n = 83)</th>
                          <th align="center" rowspan="1" colspan="1">Placebo (n = 82)</th>
                          <th align="center" rowspan="1" colspan="1">OTO-104 (n = 86)</th>
                          <th align="center" rowspan="1" colspan="1">Placebo (n = 88)</th>
                          <th align="center" rowspan="1" colspan="1">OTO-104 (n = 73)</th>
                          <th align="center" rowspan="1" colspan="1">Placebo (n = 75)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr valign="top">
                          <td align="left" colspan="2" rowspan="1">Mean Vertigo Severity Score (4-wk [28-d] interval at month 3)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1"> Adjusted mean (SE)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.408 (0.046)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.403 (0.046)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.431 (0.055)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.539 (0.055)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.425 (0.052)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.440 (0.051)</td>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1"> Difference in adjusted means (OTO-104, placebo) (SE)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.005 (0.064)</td>
                          <td rowspan="1" colspan="1"/>
                          <td align="char" char="." rowspan="1" colspan="1">−0.108 (0.078)</td>
                          <td rowspan="1" colspan="1"/>
                          <td align="char" char="." rowspan="1" colspan="1">−0.015 (0.072)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1"> <italic toggle="yes">p</italic> Value, difference in adjusted means</td>
                          <td align="center" rowspan="1" colspan="1">0.932</td>
                          <td rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">0.168</td>
                          <td rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">0.832</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr valign="top">
                          <td align="left" colspan="5" rowspan="1">Vertigo frequency (change from baseline in vertigo frequency during month 3)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1"> Adjusted mean (SE)</td>
                          <td align="char" char="." rowspan="1" colspan="1">−0.173 (0.018)</td>
                          <td align="char" char="." rowspan="1" colspan="1">−0.173 (0.018)</td>
                          <td align="char" char="." rowspan="1" colspan="1">−0.188 (0.023)</td>
                          <td align="char" char="." rowspan="1" colspan="1">−0.146 (0.023)</td>
                          <td align="char" char="." rowspan="1" colspan="1">−0.207 (0.021)</td>
                          <td align="char" char="." rowspan="1" colspan="1">−0.176 (0.021)</td>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1"> Difference in adjusted means (OTO-104, placebo) (SE)</td>
                          <td align="char" char="." rowspan="1" colspan="1">0.000 (0.025)</td>
                          <td rowspan="1" colspan="1"/>
                          <td align="char" char="." rowspan="1" colspan="1">−0.043 (0.032)</td>
                          <td rowspan="1" colspan="1"/>
                          <td align="char" char="." rowspan="1" colspan="1">−0.031 (0.029)</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1"> <italic toggle="yes">p</italic> Value, difference in adjusted means</td>
                          <td align="center" rowspan="1" colspan="1">0.993</td>
                          <td rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">0.186</td>
                          <td rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">0.282</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr valign="top">
                          <td align="left" colspan="5" rowspan="1">Effect of vertigo on days sick at home or bedridden (4-wk [28-d] during month 3)</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1">Adjusted mean days sick at home or bedridden</td>
                          <td align="center" rowspan="1" colspan="1">0.590</td>
                          <td align="center" rowspan="1" colspan="1">0.579</td>
                          <td align="center" rowspan="1" colspan="1">0.627</td>
                          <td align="center" rowspan="1" colspan="1">1.179</td>
                          <td align="center" rowspan="1" colspan="1">0.859</td>
                          <td align="center" rowspan="1" colspan="1">1.563</td>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1"> Difference in adjusted mean days sick at home or bedridden (OTO-104, placebo)</td>
                          <td align="center" rowspan="1" colspan="1">0.011</td>
                          <td rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">−0.543</td>
                          <td rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">−0.704</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1"> <italic toggle="yes">p</italic> Value, ratio in adjusted mean days sick at home or bedridden</td>
                          <td align="center" rowspan="1" colspan="1">0.943</td>
                          <td rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">0.028</td>
                          <td rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">0.053</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn fn-type="other">
                        <p>SE indicates standard error.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                  <p>In a subgroup analysis of the 115 patients (69.7% of study population) who did not previously receive intratympanic steroid injections (Table <xref rid="T4" ref-type="table">4</xref>), OTO-104 patients improved more (i.e., had lower adjusted mean DVD) from baseline than patients receiving placebo at month 3, and the difference was significant (1.895 for OTO-104 versus 3.027 for placebo; <italic toggle="yes">p</italic> = 0.045). In contrast, of the 50 patients (30.3% of the study population) who previously received intratympanic steroid injections, placebo patients had lower adjusted mean DVD (i.e., improved more) compared with patients receiving OTO-104 at month 3, and the difference was statistically significant (3.514 for OTO-104 versus 1.501 for placebo; <italic toggle="yes">p</italic> = 0.018). In addition, there was a statistically significant intratympanic steroid injection by treatment interaction (<italic toggle="yes">p</italic> = 0.006). These results suggest a potential negative impact of previous intratympanic steroid injections on results from the AVERTS-1 study.</p>
                  <table-wrap position="float" id="T4">
                    <label>TABLE 4</label>
                    <caption>
                      <p>
Effect of previous intratympanic steroid injections in the AVERTS-1 study
</p>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <thead>
                        <tr valign="top">
                          <th align="left" rowspan="1" colspan="1">Study Week Statistic</th>
                          <th align="center" rowspan="1" colspan="1">OTO-104</th>
                          <th align="center" rowspan="1" colspan="1">Placebo</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1">Month 3</td>
                          <td rowspan="1" colspan="1"/>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1">Previous intratympanic steroid injection: no</td>
                          <td align="center" rowspan="1" colspan="1">n = 63</td>
                          <td align="center" rowspan="1" colspan="1">n = 52</td>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1"> Adjusted mean DVD</td>
                          <td align="center" rowspan="1" colspan="1">1.895</td>
                          <td align="center" rowspan="1" colspan="1">3.027</td>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1"> 95% CI adjusted mean DVD</td>
                          <td align="center" rowspan="1" colspan="1">1.351–2.658</td>
                          <td align="center" rowspan="1" colspan="1">2.167–4.227</td>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1"> <italic toggle="yes">p</italic> Value, ratio of adjusted mean DVD</td>
                          <td align="center" rowspan="1" colspan="1">0.045</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1">Previous intratympanic steroid injection: yes</td>
                          <td align="center" rowspan="1" colspan="1">n = 20</td>
                          <td align="center" rowspan="1" colspan="1">n = 30</td>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1"> Adjusted mean DVD</td>
                          <td align="center" rowspan="1" colspan="1">3.514</td>
                          <td align="center" rowspan="1" colspan="1">1.501</td>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1"> 95% CI adjusted mean DVD</td>
                          <td align="center" rowspan="1" colspan="1">2.079–5.939</td>
                          <td align="center" rowspan="1" colspan="1">0.917–2.457</td>
                        </tr>
                        <tr valign="top">
                          <td align="left" rowspan="1" colspan="1"> <italic toggle="yes">p</italic> Value, ratio of adjusted mean DVD</td>
                          <td align="center" rowspan="1" colspan="1">0.018</td>
                          <td rowspan="1" colspan="1"/>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn fn-type="other">
                        <p>CI indicates confidence interval; DVD, definitive vertigo days.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
                <sec>
                  <title>AVERTS-2</title>
                  <p>As a result of the early termination of the AVERTS-2 study, there were two primary analysis populations in this study. For the main analysis population (includes all subjects who were randomized and received study drug), OTO-104 treatment was associated with significantly lower DVD than placebo at month 3 (2.3 DVDs for OTO-104 versus 3.5s DVD for placebo; <italic toggle="yes">p</italic> = 0.029; Fig. <xref rid="F2" ref-type="fig">2</xref>B). The OTO-104 treatment group had numerically greater improvement than placebo in several secondary endpoints (Table <xref rid="T3" ref-type="table">3</xref>) including mean vertigo severity score at month 3 (0.431 for OTO-104 versus 0.539 for placebo; <italic toggle="yes">p</italic> = 0.168) and change from baseline in vertigo frequency at month 3 (−0.188 for OTO-104 versus −0.146 for placebo; <italic toggle="yes">p</italic> = 0.186), neither of which achieved statistical significance; however, the OTO-104 group had significantly fewer days sick at home or bedridden at month 3 (0.627 for OTO-104 versus 1.179 for placebo; <italic toggle="yes">p</italic> = 0.028).</p>
                  <p>For the population that comprised the 111 patients (55 OTO-104 patients, 56 placebo patients) who were randomized and completed the 3 months of follow-up visits, OTO-104 treatment was associated with significantly lower DVD at month 3 than placebo (2.044 for OTO-104 versus 3.467 for placebo; <italic toggle="yes">p</italic> = 0.014). Key secondary efficacy endpoints were also significantly improved with OTO-104 treatment including mean vertigo severity score at month 3 (0.400 for OTO-104 versus 0.583 for placebo; <italic toggle="yes">p</italic> = 0.030), change from baseline in vertigo frequency at month 3 (−0.205 for OTO-104 versus −0.128 for placebo; <italic toggle="yes">p</italic> = 0.030), and effect of vertigo on days sick at home or bedridden at month 3 (0.580 for OTO-104 versus 1.083 for placebo; <italic toggle="yes">p</italic> = 0.042). The SF-36 physical and mental health summaries at month 3 were not statistically different between OTO-104 and placebo treatment groups. However, when mental health scores were analyzed individually, the OTO-104 group showed significantly improved social functioning (least squares mean difference of 3.505; <italic toggle="yes">p</italic> = 0.033) at month 3 relative to placebo.</p>
                </sec>
                <sec>
                  <title>811 Study</title>
                  <p>As indicated previously, there was a negative impact of pervious intratympanic steroid injections in the AVERTS-1 study, which may have contributed to a high placebo response. In addition, few AVERTS-2 study patients had previously been treated with intratympanic steroids and that study achieved the primary endpoint. Therefore, the 811 study excluded patients who previously received intratympanic steroid injections. Although the OTO-104 group had lower mean DVD than placebo at month 3, the difference was not significant (2.9 for OTO-104 versus 3.6 for placebo; <italic toggle="yes">p</italic> = 0.312; Fig. <xref rid="F2" ref-type="fig">2</xref>C). Secondary endpoints of mean vertigo severity score at month 3 (0.425 for OTO-104 versus 0.440 for placebo; <italic toggle="yes">p</italic> = 0.832), change from baseline in vertigo frequency at month 3 (−0.207 for OTO-104 versus −0.176 for placebo; <italic toggle="yes">p</italic> = 0.282), and effect of vertigo on days sick at home or bedridden at month 3 (0.859 for OTO-104 versus 1.563 for placebo; <italic toggle="yes">p</italic> = 0.053) generally favored OTO-104 treatment but were not significantly different between OTO 104 and placebo treatment groups (Table <xref rid="T3" ref-type="table">3</xref>). Although OTO-104 patients showed higher adjusted mean change from baseline in social health improvements (SF-36 Social Functioning Subscale) at month 3, the difference was not significant (7.7 for OTO-104 versus 5.9 for placebo; <italic toggle="yes">p</italic> = 0.259; data not shown). At month 3, the OTO-104 group had a significantly higher adjusted mean PGIC score than the placebo group (1.8 for OTO-104 versus 1.2 for placebo; <italic toggle="yes">p</italic> = 0.005), indicating that patients self-reported improvement with their Ménière's disease since the beginning of the study (data not shown).</p>
                  <p>Although all 148 patients who were randomized and received study drug in the 811 study were included in the primary analysis, 12 of these patients had major protocol deviations (e.g., received systemic steroids during the study or did not meet other eligibility criteria). For the population of 136 patients who did not have major protocol deviations (66 patients treated with OTO-104, 70 treated with placebo), the OTO-104 group had significantly lower mean DVD at month 3 than placebo (2.263 for OTO-104 versus 3.746 for placebo; <italic toggle="yes">p</italic> = 0.031). The OTO-104 treatment group in this population had significantly fewer days sick at home or bedridden at month 3 (0.8 for OTO-104 versus 1.6 for placebo; <italic toggle="yes">p</italic> = 0.026), and the OTO-104 group exhibited higher adjusted mean PGIC scores at month 3 than placebo (1.8 for OTO-104 versus 1.2 for placebo; <italic toggle="yes">p</italic> = 0.007). Other secondary endpoints including mean vertigo severity score at month 3 (0.33 for OTO-104 versus 0.45 for placebo; <italic toggle="yes">p</italic> = 0.113) and change from baseline in vertigo frequency at month 3 (−0.60 for OTO-104 versus −0.49 for placebo; <italic toggle="yes">p</italic> = 0.113) favored OTO-104 treatment but did not achieve statistical significance.</p>
                  <p>The 811 study was conducted from August 27, 2018, to December 22, 2020, and therefore was impacted by COVID-19. In those instances where patients could not travel to the site or chose not to because of COVID-19 restrictions, sites could conduct scheduled clinic visits remotely. Twenty-eight patients (18.8% of study population) had at least one visit impacted by COVID-19. However, because the primary and key secondary efficacy assessments were collected via phone as originally planned, it was concluded that there was no impact on study conduct or data because of COVID-19 pandemic restrictions.</p>
                  <p>Further information regarding diary compliance and safety is provided as Supplemental Appendix E, <ext-link xlink:href="http://links.lww.com/MAO/B623" ext-link-type="uri">http://links.lww.com/MAO/B623</ext-link>, and Appedix F, <ext-link xlink:href="http://links.lww.com/MAO/B624" ext-link-type="uri">http://links.lww.com/MAO/B624</ext-link>, respectively. Supplemental information regarding treatment-emergent adverse events is provided in Supplemental Table 1, <ext-link xlink:href="http://links.lww.com/MAO/B617" ext-link-type="uri">http://links.lww.com/MAO/B617</ext-link>. A summary of the incidence of tympanic membrane perforations is provided in Supplemental Table 2, <ext-link xlink:href="http://links.lww.com/MAO/B618" ext-link-type="uri">http://links.lww.com/MAO/B618</ext-link>.</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>DISCUSSION</title>
              <p>OTO-104 is a poloxamer-based formulation that has both sustained-exposure and mucoadhesive properties providing a sustained concentration of dexamethasone within the inner ear. Animal models have shown that a single intratympanic injection of OTO-104 may have drug exposure advantages over intratympanic corticosteroid solutions (<xref rid="bib13" ref-type="bibr">13</xref>). Intratympanic delivery allows the thermosensitive poloxamer to be placed at the round window niche where it deposits dexamethasone as a depot for sustained drug diffusion into the inner ear. This is in contrast to the high variability and transient inner ear steroid concentrations observed after intratympanic injection of solution-based formulations (<xref rid="bib22" ref-type="bibr">22</xref>,<xref rid="bib23" ref-type="bibr">23</xref>). The thermosensitive properties of OTO-104 provide other practical advantages over the use of conventional steroid solutions. After administration of OTO-104, patients are able to sit upright immediately and do not need to remain laterally recumbent for up to 30 minutes with no talking or swallowing, as is generally required after administration of solutions. This offers patient acceptance and convenience over current clinical practice of multiple intratympanic injections of steroid solution per course of treatment.</p>
              <p>Three large, high-quality clinical trials have found OTO-104 to be safe and well tolerated. Although OTO-104 was effective for reducing vertigo during the 3 months after the injection, demonstrating numerically greater reductions in vertigo across all three studies, statistical significance was only achieved in one of the studies. This outcome is disappointing both for researchers in the area of Ménière's disease and, more importantly, for patients with Ménière's disease, who are in desperate need for a safe, reliable, evidence-based treatment for their symptoms.</p>
              <p>It is important to note that the placebo response was remarkably high in each study, ranging from approximately 73% in AVERTS-1 to 62% and 61% in AVERTS-2 and 811 studies, respectively. In fact, the placebo response rates observed here were higher than those previously reported for other subjective conditions using patient-reported outcomes including depression (<xref rid="bib24" ref-type="bibr">24</xref>). Procedures for minimizing placebo response were implemented for the 811 study (i.e., patient video describing the purpose of clinical research and the role of the patient in placebo-controlled trials; investigator and staff training on ways to manage placebo response), yet the placebo response remained high. Possible factors contributing to the placebo response include expectation bias such that an improvement was expected based on participating in the clinical trial and receiving an intervention; the use of an injection, which may be associated with higher placebo response compared with oral medications (<xref rid="bib25" ref-type="bibr">25</xref>); and regression to the mean with respect to vertigo, which is episodic in nature. Expectations of benefit based on pervious intratympanic steroid injections may have been a factor in the AVERTS-1 study, but their use was either limited or excluded in the other two studies. Similar observations of high placebo response were noted in the evaluation of orally administered betahistine in Ménière's disease (<xref rid="bib26" ref-type="bibr">26</xref>) whereby a significant decline of vertigo attack rates was demonstrated for placebo and betahistine treatment groups.</p>
              <p>Ménière's disease suffers from a lack of understanding of its underlying pathology, consequently complicating accurate design of therapeutic trials. Although the preponderance of evidence, including radiographic, experimental, and human temporal bone data, shows that endolymphatic hydrops has been accepted as part of the pathology of Ménière's disease (<xref rid="bib27" ref-type="bibr">27</xref>), the cause of hydrops remains unknown and might very well represent an epiphenomenon (<xref rid="bib28" ref-type="bibr">28</xref>).</p>
              <p>During the 5 plus years it took to complete the series of trials described here, the understanding and treatment of Ménière's disease progressed in the community. Particularly in the United States, it is the author's impression (A.A.M.) that intratympanic injection by community otolaryngologists became increasingly widespread, making it more challenging to recruit treatment-naive patients; a similar observation has been witnessed in the United Kingdom. The initial phase 3 study (AVERTS-1), attempting to duplicate the enrollment of the successful phase 2 study, did not control for patients who had failed previous intratympanic injection of aqueous steroid. Thus, it is possible that this helped select for nonresponders to steroid therapy, as more patients were being injected in the community as time progressed. This is consistent with the negative impact experienced by the 50 patients who previously received intratympanic steroids on study outcomes in this trial. The 811 trial adjusted to this possibility by excluding patients who had previously undergone aqueous steroid injection, although this did not lead to a positive result. It is interesting that when evaluating the per-protocol study population in 811 (excluding the 12 subjects with major protocol deviations), there was a significant benefit of OTO-104 over placebo. Several of these patients received systemic steroids as a rescue treatment for their vertigo while on study (prohibited per study eligibility criteria), suggesting that their symptoms were particularly severe during the study. For both negative trials, the fact that evaluation of subsets of large numbers of patients yielded positive results could provide learnings for future studies.</p>
              <p>Vestibular migraine, also known as migraine-associated dizziness and other similar monikers, is a disease process that can mimic symptoms of Ménière's disease. Vestibular migraine was an exclusion criterion for the studies described here, but given the overlap of symptoms between vestibular migraine and Ménière's disease, exclusion of migraine patients based solely on history is challenging. Patients who initially have what seem to be clear symptoms of Ménière's disease can over time morph into vestibular migraine (authors impression—A.A.M.). This is worthy of reflection in the context of how many authors have considered Menière's disease to represent the final pathway of a number of candidate causes, rather than being the consequence of a single isolated pathology (<xref rid="bib28" ref-type="bibr">28</xref>). Subgroups of Ménière's disease have been defined according to clinical aspects, radiological features, and inflammatory cytokine profiling (<xref rid="bib29" ref-type="bibr">29</xref>–<xref rid="bib31" ref-type="bibr">31</xref>). It is worthy of reflection that the studies described in this article did not consider subtyping participants according to family history, history of migraine, or history of autoimmune disorder. Furthermore, it has been suggested that inflammatory cytokine profiling might determine the response to the provision of steroids, according to IL-1β, TNF-α, IL-6, and IL-1RA levels (<xref rid="bib31" ref-type="bibr">31</xref>).</p>
              <sec>
                <title>How Do We Interpret These Findings in the Context of What We Understand From Other Research?</title>
                <p>In 2016, Patel et al. (<xref rid="bib16" ref-type="bibr">16</xref>) published the findings of a randomized, double-blind, comparative effectiveness trial that compared intratympanic methylprednisolone with gentamicin in patients with unilateral Ménière's disease. This trial found that the effectiveness of intratympanic methylprednisolone was comparable with that of gentamicin. This was a high-quality clinical trial that assessed outcomes at 2 years. There are three possible explanations for why OTO-104 failed to consistently demonstrate a statistically significant benefit over placebo in the context of the Patel study:</p>
                <list list-type="order">
                  <list-item>
                    <p>The Patel study did not include a control group. One possibility is that corticosteroids and aminoglycosides are both ineffective in the treatment of Ménière's disease, and that the effects witnessed are entirely the consequences of placebo.</p>
                  </list-item>
                  <list-item>
                    <p>It might be that we need to reconsider the window for recording outcomes. The effects of corticosteroids are not evident in the shorter term (3 mo) but might be evident in the longer term (12–24 mo).</p>
                  </list-item>
                  <list-item>
                    <p>As noted previously, a high placebo response is frequently witnessed when studying interventions for neurotological symptoms such as vertigo and tinnitus, with the natural course of these symptoms often being that of natural reversion as the underlying cause acquiesces. With this in mind, the beneficial effects of OTO-104 could not consistently be statistically separated from the high placebo response observed in these studies.</p>
                  </list-item>
                </list>
                <sec>
                  <title>Implications for Practice</title>
                  <p>There is conflicting evidence to support the use of intratympanic corticosteroids to treat patients suffering from the effects of Ménière's disease. Although all three OTO-104 studies outlined previously showed numerical benefit, they do not allow us to confirm the effectiveness of corticosteroids to the highest research standards. However, it should be appreciated that for the two negative studies, subgroup analyses revealed significant benefit in favor of OTO-104, patients did notice an improvement in their quality of life in one of the negative studies, and the safety profile of this intervention was excellent in all three studies.</p>
                  <p>This series of studies should not mark the end of the use of intratympanic steroids in the clinical treatment of Menière's disease for several reasons. First, it remains undetermined whether intratympanic steroids might be beneficial for the treatment of some subsets of Ménière's disease sufferers. Given that the risk of harm from intratympanic injection is largely limited to a small rate of tympanic membrane perforation, it is reasonable for the clinician to attempt a trial of intratympanic steroids. Second, the series of studies summarized here consistently show a high placebo response, which in and of itself is efficacious as a treatment, particularly in light of the fact that the safety profile of intratympanic steroid injection is excellent. Third, further studies involving other steroids and patients selected to have Ménière's disease through MRI of hydrops or via other novel methods might improve the diagnostic certainty of the underlying condition resulting in Ménière's disease symptoms and subsequently improve the efficacy of intratympanic steroid therapy (<xref rid="bib32" ref-type="bibr">32</xref>).</p>
                </sec>
                <sec>
                  <title>Implications for Future Research in This Area</title>
                  <p>The three OTO-104 studies described in this article represent the largest high-quality trials of a nondestructive drug treatment for patients with Ménière's disease. These studies were all conducted with every effort to reduce bias and enforce accurate data reporting. It is hoped that despite the fact that research into OTO-104 will now cease, other researchers and industry will continue to invest their time, effort, and resources into considering effective treatments for patients with Ménière's disease. Determining how to best manage placebo response in this episodic and subjective condition is a key hurdle for the field.</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <fig id="s001" position="anchor">
                <media xlink:href="on-44-0584-s001.pdf"/>
              </fig>
              <fig id="s002" position="anchor">
                <media xlink:href="on-44-0584-s002.docx"/>
              </fig>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgments</title>
              <p>The authors thank the patients and their caregivers, the clinical study site staff members, study coordinators, nursing and supporting staff, and remaining members of the study teams for their participation in this study (see Supplemental Appendix G, <ext-link xlink:href="http://links.lww.com/MAO/B625" ext-link-type="uri">http://links.lww.com/MAO/B625</ext-link>, for a list of principal investigators).</p>
            </ack>
            <fn-group>
              <fn fn-type="financial-disclosure">
                <p>Sources of support and disclosure of funding: J.P. and A.A.M.'s institutions received clinical study funding from Otonomy, Inc. J.P. and A.A.M. have received financial compensation from Otonomy, Inc., in the past but not related to the role as investigator in this study. J.P. has received funding for his Ménière's disease research by the UK Medical Research Council and the UK National Institute of Health Research, but his views herein are his own and do not represent those of the UK Medical Research Council, the UK National Institute of Health Research, or the UK Department of Health and Social Care. J.M.R., J.J.A., and D.S. are employees of and own stock options and/or stock in Otonomy, Inc. The study and analyses were financially supported by Otonomy, Inc (clinical trial registration numbers: NCT02727442, NCT02612337, NCT03664674).</p>
              </fn>
              <fn fn-type="other">
                <p>Data sharing statement: The data from this study will not be shared publicly.</p>
              </fn>
              <fn fn-type="other">
                <p>Supplemental digital content is available in the text.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="bib1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><collab collab-type="authors">Committee on Hearing and Equilibrium (CHE)</collab></person-group>. <article-title>Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Ménière's disease</article-title>. <source><italic toggle="yes">Otolaryngol Head Neck Surg</italic></source><year>1995</year>;<volume>113</volume>:<fpage>181</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">7675476</pub-id></mixed-citation>
              </ref>
              <ref id="bib2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Lopez-Escamez</surname><given-names>JA</given-names></name><name><surname>Carey</surname><given-names>J</given-names></name><name><surname>Chung</surname><given-names>WH</given-names></name>, <etal/></person-group>. <article-title>Diagnostic criteria for Ménière's disease</article-title>. <source><italic toggle="yes">J Vestib Res</italic></source><year>2015</year>;<volume>25</volume>:<fpage>1</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">25882471</pub-id></mixed-citation>
              </ref>
              <ref id="bib3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Harris</surname><given-names>JP</given-names></name><name><surname>Alexander</surname><given-names>TH</given-names></name></person-group>. <article-title>Current-day prevalence of Ménière's syndrome</article-title>. <source><italic toggle="yes">Audiol Neurootol</italic></source><year>2010</year>;<volume>15</volume>:<fpage>318</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">20173319</pub-id></mixed-citation>
              </ref>
              <ref id="bib4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Wladislavosky-Waserman</surname><given-names>P</given-names></name><name><surname>Facer</surname><given-names>GW</given-names></name><name><surname>Mokri</surname><given-names>B</given-names></name><name><surname>Kurland</surname><given-names>LT</given-names></name></person-group>. <article-title>Ménière's disease: A 30-year epidemiologic and clinical study in Rochester, Mn, 1951–1980</article-title>. <source><italic toggle="yes">Laryngoscope</italic></source><year>1984</year>;<volume>94</volume>:<fpage>1098</fpage>–<lpage>102</lpage>.<pub-id pub-id-type="pmid">6611471</pub-id></mixed-citation>
              </ref>
              <ref id="bib5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Anderson</surname><given-names>JP</given-names></name><name><surname>Harris</surname><given-names>JP</given-names></name></person-group>. <article-title>Impact of Ménière's disease on quality of life</article-title>. <source><italic toggle="yes">Otol Neurotol</italic></source><year>2001</year>;<volume>22</volume>:<fpage>888</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">11698814</pub-id></mixed-citation>
              </ref>
              <ref id="bib6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Porter</surname><given-names>M</given-names></name><name><surname>Boothroyd</surname><given-names>RA</given-names></name></person-group>. <article-title>Symptom severity, social supports, coping styles, and quality of life among individuals' diagnosed with Ménière's disease</article-title>. <source><italic toggle="yes">Chronic Illn</italic></source><year>2015</year>;<volume>11</volume>:<fpage>256</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">25595277</pub-id></mixed-citation>
              </ref>
              <ref id="bib7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Tyrrell</surname><given-names>J</given-names></name><name><surname>Whinney</surname><given-names>DJ</given-names></name><name><surname>Taylor</surname><given-names>T</given-names></name></person-group>. <article-title>The cost of Ménière's disease: A novel multisource approach</article-title>. <source><italic toggle="yes">Ear Hear</italic></source><year>2016</year>;<volume>37</volume>:<fpage>e202</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">26760200</pub-id></mixed-citation>
              </ref>
              <ref id="bib8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Gupta</surname><given-names>BBP</given-names></name><name><surname>Lalchhandama</surname><given-names>K</given-names></name></person-group>. <article-title>Molecular mechanisms of glucocorticoid action</article-title>. <source><italic toggle="yes">Curr Sci</italic></source><year>2002</year>;<volume>83</volume>:<fpage>1103</fpage>–<lpage>11</lpage>.</mixed-citation>
              </ref>
              <ref id="bib9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Garduño-Anaya</surname><given-names>MA</given-names></name><name><surname>De Toledo</surname><given-names>HC</given-names></name><name><surname>Hinojosa-González</surname><given-names>R</given-names></name><name><surname>Pane-Pianese</surname><given-names>C</given-names></name><name><surname>Ríos-Castañeda</surname><given-names>LC</given-names></name></person-group>. <article-title>Dexamethasone inner ear perfusion by intratympanic injection in unilateral Ménière's disease: A two-year prospective, placebo-controlled, double-blind, randomized trial</article-title>. <source><italic toggle="yes">Otolaryngol Head Neck Surg</italic></source><year>2005</year>;<volume>133</volume>:<fpage>285</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">16087029</pub-id></mixed-citation>
              </ref>
              <ref id="bib10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Boleas-Aguirre</surname><given-names>MS</given-names></name><name><surname>Lin</surname><given-names>FR</given-names></name><name><surname>Della Santina</surname><given-names>CC</given-names></name><name><surname>Minor</surname><given-names>LB</given-names></name><name><surname>Carey</surname><given-names>JP</given-names></name></person-group>. <article-title>Longitudinal results with intratympanic dexamethasone in the treatment of Ménière's disease</article-title>. <source><italic toggle="yes">Otol Neurotol</italic></source><year>2008</year>;<volume>29</volume>:<fpage>33</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">18199956</pub-id></mixed-citation>
              </ref>
              <ref id="bib11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Farhood</surname><given-names>Z</given-names></name><name><surname>Lambert</surname><given-names>PR</given-names></name></person-group>. <article-title>The physiologic role of corticosteroids in Ménière's disease</article-title>. <source><italic toggle="yes">Am J Otolaryngol</italic></source><year>2016</year>;<volume>37</volume>:<fpage>455</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">27221028</pub-id></mixed-citation>
              </ref>
              <ref id="bib12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Pondugula</surname><given-names>SR</given-names></name><name><surname>Sanneman</surname><given-names>JD</given-names></name><name><surname>Wangemann</surname><given-names>P</given-names></name><name><surname>Milhaud</surname><given-names>PG</given-names></name><name><surname>Marcus</surname><given-names>DC</given-names></name></person-group>. <article-title>Glucocorticoids stimulate cation absorption by semicircular canal duct epithelium via epithelial sodium channel</article-title>. <source><italic toggle="yes">Am J Physiol Renal Physiol</italic></source><year>2004</year>;<volume>286</volume>:<fpage>F1127</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">14996671</pub-id></mixed-citation>
              </ref>
              <ref id="bib13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Piu</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Fernandez</surname><given-names>R</given-names></name>, <etal/></person-group>. <article-title>OTO-104: A sustained release dexamethasone hydrogel for the treatment of otic disorders</article-title>. <source><italic toggle="yes">Otol Neurotol</italic></source><year>2011</year>;<volume>32</volume>:<fpage>171</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">21099726</pub-id></mixed-citation>
              </ref>
              <ref id="bib14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Lambert</surname><given-names>PR</given-names></name><name><surname>Nguyen</surname><given-names>S</given-names></name><name><surname>Maxwell</surname><given-names>KS</given-names></name>, <etal/></person-group>. <article-title>A randomized, double-blind, placebo-controlled clinical study to assess safety and clinical activity of OTO-104 given as a single intratympanic injection in patients with unilateral Ménière's disease</article-title>. <source><italic toggle="yes">Otol Neurotol</italic></source><year>2012</year>;<volume>33</volume>:<fpage>1257</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">22858715</pub-id></mixed-citation>
              </ref>
              <ref id="bib15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Lambert</surname><given-names>PR</given-names></name><name><surname>Carey</surname><given-names>J</given-names></name><name><surname>Mikulec</surname><given-names>AA</given-names></name><name><surname>LeBel</surname><given-names>C</given-names></name>, <collab collab-type="authors">Otonomy Ménièreʼs Study Group</collab></person-group>. <article-title>Intratympanic sustained-exposure dexamethasone thermosensitive gel for symptoms of Ménière's disease: Randomized phase 2b safety and efficacy trial</article-title>. <source><italic toggle="yes">Otol Neurotol</italic></source><year>2016</year>;<volume>37</volume>:<fpage>1669</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">27749754</pub-id></mixed-citation>
              </ref>
              <ref id="bib16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Patel</surname><given-names>M</given-names></name><name><surname>Agarwal</surname><given-names>K</given-names></name><name><surname>Arshad</surname><given-names>Q</given-names></name>, <etal/></person-group>. <article-title>Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière's disease: A randomised, double-blind, comparative effectiveness trial</article-title>. <source><italic toggle="yes">Lancet</italic></source><year>2016</year>;<volume>388</volume>:<fpage>2753</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">27865535</pub-id></mixed-citation>
              </ref>
              <ref id="bib17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><collab collab-type="authors">World Medical Association</collab></person-group>. <article-title>World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects</article-title>. <source><italic toggle="yes">JAMA</italic></source><year>2013</year>;<volume>310</volume>:<fpage>2191</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">24141714</pub-id></mixed-citation>
              </ref>
              <ref id="bib18">
                <label>18</label>
                <mixed-citation publication-type="book"><person-group><collab collab-type="authors">ICH Expert Working Group, ICH Expert Working Group</collab></person-group>. <source><italic toggle="yes">ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1)</italic></source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>ICH</publisher-name>; <year>1996</year>.</mixed-citation>
              </ref>
              <ref id="bib19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Gates</surname><given-names>GA</given-names></name></person-group>. <article-title>Clinimetrics of Ménière's disease</article-title>. <source><italic toggle="yes">Laryngoscope</italic></source><year>2000</year>;<volume>110, 110</volume>(<issue>3 Pt 3</issue>):<fpage>8</fpage>–<lpage>11</lpage>.</mixed-citation>
              </ref>
              <ref id="bib20">
                <label>20</label>
                <mixed-citation publication-type="book"><person-group><name><surname>Ware</surname><given-names>JE</given-names></name><name><surname>Snow</surname><given-names>KK</given-names></name><name><surname>Kosinski</surname><given-names>B</given-names></name><name><surname>Gandek</surname><given-names>B</given-names></name></person-group>. <source><italic toggle="yes">SF-36 Health Survey: Manual and Interpretation Guide</italic></source>. <publisher-loc>Boston, MA</publisher-loc>: <publisher-name>The Health Institute, New England Medical Center</publisher-name>; <year>1993</year>.</mixed-citation>
              </ref>
              <ref id="bib21">
                <label>21</label>
                <mixed-citation publication-type="book"><person-group><name><surname>Ware</surname><given-names>JE</given-names></name></person-group>. <article-title>SF-36 Physical &amp; Mental Health Summary Scales: A User's Manual</article-title>. <publisher-loc>Boston, MA</publisher-loc>: <publisher-name>Quality Metric</publisher-name>; <year>1994</year>.</mixed-citation>
              </ref>
              <ref id="bib22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Bird</surname><given-names>PA</given-names></name><name><surname>Begg</surname><given-names>EJ</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name>, <etal/></person-group>. <article-title>Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph</article-title>. <source><italic toggle="yes">Otol Neurotol</italic></source><year>2007</year>;<volume>28</volume>:<fpage>1124</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">18043438</pub-id></mixed-citation>
              </ref>
              <ref id="bib23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Bird</surname><given-names>PA</given-names></name><name><surname>Murray</surname><given-names>DP</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Begg</surname><given-names>EJ</given-names></name></person-group>. <article-title>Intratympanic versus intravenous delivery of dexamethasone and dexamethasone sodium phosphate to cochlear perilymph</article-title>. <source><italic toggle="yes">Otol Neurotol</italic></source><year>2011</year>;<volume>32</volume>:<fpage>933</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">21725263</pub-id></mixed-citation>
              </ref>
              <ref id="bib24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Papakostas</surname><given-names>GI</given-names></name><name><surname>Fava</surname><given-names>M</given-names></name></person-group>. <article-title>Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD</article-title>. <source><italic toggle="yes">Eur Neuropsychopharmacol</italic></source><year>2009</year>;<volume>19</volume>:<fpage>34</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">18823760</pub-id></mixed-citation>
              </ref>
              <ref id="bib25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Bannuru</surname><given-names>RR</given-names></name><name><surname>McAlindon</surname><given-names>TE</given-names></name><name><surname>Sullivan</surname><given-names>MC</given-names></name>, <etal/></person-group>. <article-title>Effectiveness and implications of alternative placebo treatments: A systematic review and network meta-analysis of osteoarthritis trials</article-title>. <source><italic toggle="yes">Ann Intern Med</italic></source><year>2015</year>;<volume>163</volume>:<fpage>365</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">26215539</pub-id></mixed-citation>
              </ref>
              <ref id="bib26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Adrion</surname><given-names>C</given-names></name><name><surname>Fischer</surname><given-names>CS</given-names></name><name><surname>Wagner</surname><given-names>J</given-names></name>, <etal/></person-group>. <article-title>Efficacy and safety of betahistine treatment in patients with Meniere's disease: Primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial)</article-title>. <source><italic toggle="yes">BMJ</italic></source><year>2016</year>;<volume>352</volume>:<fpage>h6816</fpage>.<pub-id pub-id-type="pmid">26797774</pub-id></mixed-citation>
              </ref>
              <ref id="bib27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Hallpike</surname><given-names>CS</given-names></name><name><surname>Cairns</surname><given-names>H</given-names></name></person-group>. <article-title>Observations on the pathology of Meniere's syndrome: (Section of Otology)</article-title>. <source><italic toggle="yes">Proc R Soc Med</italic></source><year>1938</year>;<volume>31</volume>:<fpage>1317</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="pmid">19991672</pub-id></mixed-citation>
              </ref>
              <ref id="bib28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Phillips</surname><given-names>JS</given-names></name><name><surname>Murdin</surname><given-names>L</given-names></name><name><surname>Rea</surname><given-names>P</given-names></name><name><surname>Sutton</surname><given-names>L</given-names></name></person-group>. <article-title>Clinical subtyping of Ménière's disease</article-title>. <source><italic toggle="yes">Otolaryngol Head Neck Surg</italic></source><year>2018</year>;<volume>159</volume>:<fpage>407</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">29688822</pub-id></mixed-citation>
              </ref>
              <ref id="bib29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Frejo</surname><given-names>L</given-names></name><name><surname>Martin-Sanz</surname><given-names>E</given-names></name><name><surname>Teggi</surname><given-names>R</given-names></name>, <etal/>, <collab collab-type="authors">Meniere's Disease Consortium (MeDiC)</collab></person-group>. <article-title>Extended phenotype and clinical subgroups in unilateral Meniere disease: A cross-sectional study with cluster analysis</article-title>. <source><italic toggle="yes">Clin Otolaryngol</italic></source><year>2017</year>;<volume>42</volume>:<fpage>1172</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="pmid">28166395</pub-id></mixed-citation>
              </ref>
              <ref id="bib30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Bächinger</surname><given-names>D</given-names></name><name><surname>Luu</surname><given-names>NN</given-names></name><name><surname>Kempfle</surname><given-names>JS</given-names></name>, <etal/></person-group>. <article-title>Vestibular aqueduct morphology correlates with endolymphatic sac pathologies in Menière's disease—A correlative histology and computed tomography study</article-title>. <source><italic toggle="yes">Otol Neurotol</italic></source><year>2019</year>;<volume>40</volume>:<fpage>e548</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">31083097</pub-id></mixed-citation>
              </ref>
              <ref id="bib31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Frejo</surname><given-names>L</given-names></name><name><surname>Gallego-Martinez</surname><given-names>A</given-names></name><name><surname>Requena</surname><given-names>T</given-names></name>, <etal/></person-group>. <article-title>Proinflammatory cytokines and response to molds in mononuclear cells of patients with Meniere disease</article-title>. <source><italic toggle="yes">Sci Rep</italic></source><year>2018</year>;<volume>8</volume>:<fpage>5974</fpage>.<pub-id pub-id-type="pmid">29654306</pub-id></mixed-citation>
              </ref>
              <ref id="bib32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group><name><surname>Phillips</surname><given-names>JS</given-names></name><name><surname>Newman</surname><given-names>JL</given-names></name><name><surname>Cox</surname><given-names>SJ</given-names></name></person-group>. <article-title>Clinical techniques and technology: Vestibular telemetry</article-title>. <source><italic toggle="yes">Otolaryngol Head Neck Surg</italic></source><year>2021</year>;<volume>165</volume>:<fpage>751</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="pmid">33650899</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
